These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 28386105)

  • 1. Measurable residual disease testing in acute myeloid leukaemia.
    Hourigan CS; Gale RP; Gormley NJ; Ossenkoppele GJ; Walter RB
    Leukemia; 2017 Jul; 31(7):1482-1490. PubMed ID: 28386105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving MRD negativity in AML: how important is this and how do we get there?
    Hourigan CS
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):9-14. PubMed ID: 36485093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
    Blackmon AL; Hourigan CS
    Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
    Revoltar M; van der Linde R; Cromer D; Gatt PN; Smith S; Fernandez MA; Vaughan L; Blyth E; Curnow J; Tegg E; Brown DA; Sasson SC
    Pathology; 2024 Oct; 56(6):882-888. PubMed ID: 39025727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
    Roug AS; Ommen HB
    Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.
    Walter RB; Ofran Y; Wierzbowska A; Ravandi F; Hourigan CS; Ngai LL; Venditti A; Buccisano F; Ossenkoppele GJ; Roboz GJ
    Leukemia; 2021 Jun; 35(6):1529-1538. PubMed ID: 33758317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.
    Meddi E; Savi A; Moretti F; Mallegni F; Palmieri R; Paterno G; Buzzatti E; Del Principe MI; Buccisano F; Venditti A; Maurillo L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
    Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods of Detection of Measurable Residual Disease in AML.
    Zhou Y; Wood BL
    Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of measurable residual disease in AML: Review of current evidence.
    Moors I; Vandepoele K; Philippé J; Deeren D; Selleslag D; Breems D; Straetmans N; Kerre T; Denys B
    Crit Rev Oncol Hematol; 2019 Jan; 133():142-148. PubMed ID: 30661650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
    Pettit K; Stock W; Walter RB
    Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Skou AS; Juul-Dam KL; Ommen HB; Hasle H
    Br J Haematol; 2021 Nov; 195(3):310-327. PubMed ID: 33851435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Juul-Dam KL; Ommen HB; Nyvold CG; Walter C; Vålerhaugen H; Kairisto V; Abrahamsson J; Alm SJ; Jahnukainen K; Lausen B; Reinhardt D; Zeller B; von Neuhoff N; Fogelstrand L; Hasle H
    Br J Haematol; 2020 Jul; 190(2):198-208. PubMed ID: 32175599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease in acute myeloid leukaemia.
    Hourigan CS; Karp JE
    Nat Rev Clin Oncol; 2013 Aug; 10(8):460-71. PubMed ID: 23799371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.